

# The future of APC management: Access to treatments

Karim Fizazi


Institut Gustave Roussy

France




# Incidence of cancer vs Anti-cancer drug sales

Anti-Cancer Drug Sales



Cancer



USA  
Japan

Europe  
Rest of World

# ACCESS TO RADIOTHERAPY

pact@iaea.org




**Radiotherapy is an essential part of the treatment of cancer**

**Over 30 African and Asian countries have no access to radiotherapy**

**There is a shortfall of over 5000 radiotherapy machines in the developing world**

**IAEA has initiated PACT to comprehensively address this urgent problem, and is moving its radiotherapy programmes to a public health model.**

Copyright 2006 American Cancer Society, INC. / Reprinted with permission



## Availability of treatment

Number of people served by a single radiotherapy centre (latest available data 1995–2003)



Programme of  
Action for  
Cancer  
Therapy  
**PACT**

Cavalli F, APCCC 2017

By William H. Shrank, Niteesh K. Choudhry, Joshua N. Liberman, and Troyen A. Brennan


---

# The Use Of Generic Drugs In Prevention Of Chronic Disease Is Far More Cost-Effective Than Thought, And May Save Money

appropriate use of generic medications, appears far more cost-effective than previously documented, and it may even save on costs. For example, an earlier study estimated that reducing blood pressure to widely established clinical guidelines in nondiabetic patients cost an estimated \$52,983 per quality-adjusted life-year if a brand-name drug was used. However, we estimate that the cost is just \$7,753 per quality-adjusted life-year at generic medication prices. As the nation attempts to find

**DOI:** 10.1377/hlthaff.2010.0431  
HEALTH AFFAIRS 30,  
NO. 7 (2011): 1351-1357  
©2011 Project HOPE—  
The People-to-People Health  
Foundation, Inc.

# Docetaxel



- Before loss of exclusivity:
  - About **1500 €/cycle**
- Current price (generics):
  - About **20 €/cycle**



# The economic impact of the transition from branded to generic oncology drugs

W.Y. Cheung MD MPH,\* E.A. Kornelsen BSc,\* N. Mittmann PhD,<sup>†</sup> N.B. Leighl MD MMSc,<sup>†</sup>  
M. Cheung MD MSc,<sup>†</sup> K.K. Chan MD MSc MSc,<sup>†</sup> P.A. Bradbury MB BCh,<sup>†</sup> R.C.H. Ng MD,<sup>†</sup> B.E. Chen PhD,<sup>‡</sup>  
K. Ding PhD,<sup>‡</sup> J.L. Pater MD,<sup>‡</sup> D. Tu PhD,<sup>‡</sup> and A.E. Hay MB ChB<sup>‡</sup>

value-based allocation of health care resources. At current levels, the costs of generics might not be sufficiently low to sustain publicly funded health care systems.

# Prostate cancer drugs in the 2010's

**Abiraterone**


**Cabazitaxel**

**Enzalutamide**


**Radium-223**

**Denosumab**

# Expected access to generic Abiraterone in 2019 (results from an informal survey)



# Abiraterone generics



- US: Generics authorized in Oct 2018
  - Coupons for non-insured: 2500 \$/m (instead of 9000 \$ for branded Abiraterone)
  - But no major change for insured pts...
- Brasil: 6 generics:
  - 1300-2300 \$ generics (instead of 3000 \$ branded)
- EU: Abi patent protected until Sept 2022

# There may be an alternative to abiraterone generics...

VOLUME 36 • NUMBER 14 • MAY 10, 2018

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT


## Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

*Russell Z. Szmulewitz, Cody J. Peer, Abiola Ibraheem, Elia Martinez, Mark F. Kozloff, Bradley Carthon, R. Donald Harvey, Paul Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D. Figg, Walter M. Stadler, and Mark J. Ratain*

### **Conclusion**

Low-dose AA (with low-fat breakfast) is noninferior to standard dosing with respect to PSA metrics. Given the pharmacoeconomic implications, these data warrant consideration by prescribers, payers, and patients. Additional studies are indicated to assess the long-term efficacy of this approach.

# Cabazitaxel



- 10 years exclusivity after approval
- Generics expected starting in 2021




CARD RCT data likely to be shown at ESMO

# Expected loss of patent

• Denosumab	2025
• Enzalutamide	2027
• Radium-223	?
• Darolutamide	?
• Apalutamide	2032

# Saving money: Surgical castration vs LHRH agonists/antagonists

## Toronto



## San Francisco

n= 10,000 M1 pts

Likelihood to receive Surgical ADT:

- Hispanic: OR=1.3
- Low socio-economic status: OR=2
- Rural area: OR=1.5
- Medicaid/Public insurance: OR=2.2

Krahn MD, Curr Oncol 2016  
Borno HD, Cancer 2019

# Thank you to all those who helped

- Chris Sweeney
- Andre Fay
- Louis Kayitalire
- Anne-Emmanuelle Maas
- Frank Verholen
- Suneel Mundle
- Christine Geffriaud
- Alexis Serikoff
- Romain Desmaris
- Sylvie Richard